The seminar on precision medical industrialization sponsored by the Precision Medicine and Cancer Rehabilitation Committee of the China Rehabilitation Technology Transformation and Development Promotion Association was held on the afternoon of May 26 at the Unbounded Space (Wangjing) in Chaoyang District, Beijing. This salon invited Professor Zhou Xiaoguang, the expert of the “Thousand Talents Program†of the Central Organization Department, the Chief Medical Officer of Zhongyuan Concord, Dr. Li Hongtao, an expert of Tianjin “Innovative Thousand Talents Programâ€, Cai Daqing, Managing Director of Junlian Capital, and Chairman of Huasheng Hengye Raojiang and well-known corporate people participated in this event to focus on the development path of precision medical industrialization. Yan Wei, Secretary-General of China Rehabilitation Technology Transformation and Development Promotion Association, and Song Buchen, Deputy Secretary-General, attended the event. Secretary-General Yan Wei delivered a speech. Yu Xiaoguang, Deputy Secretary-General of Precision Medicine and Tumor Rehabilitation Committee of China Rehabilitation Technology Transformation and Development Promotion Association Event hosting. Zhou Xiaoguang, Researcher, Institute of Semiconductors, Chinese Academy of Sciences, Doctoral Supervisor Professor Zhou Xiaoguang is a researcher at the Institute of Semiconductors of the Chinese Academy of Sciences and a doctoral tutor. In 2011, the “Thousand Talents Program†of the National Central Organization Department introduced high-level talents overseas. Deputy Director of the Precision Medicine and Tumor Rehabilitation Committee of the China Rehabilitation Technology Transformation and Development Promotion Association. Foreign expert and visiting professor at the Beijing Institute of Genomics, Chinese Academy of Sciences. Professor Zhou Xiaoguang has long been engaged in the research of life science analysis tools and the development of high-end instruments. He has served as a scientist, senior engineer, chief engineer and project leader of the American Thermoelectric Instrument Company. He is also the project development manager, research and development department senior manager and research and development manager of Applied Biosystems. 1. From the late 1990s to the 2001-2003 recession, gene sequencing experienced a bubble period. In the mid-to-late 1980s, sequencing technology promoted the development of genomics. In addition, mass spectrometry created a proteomics discipline through high-throughput protein analysis. At the beginning of this century, the completion of the Human Genome Project marked the dawn of the genomics era. The main driving force was that around 1995, the company I originally worked on developed the first generation of sequencers. Later, the emergence of ABI3700 greatly accelerated the completion of the Human Genome Project. Around 2001, we saw the first genomic bubble. The above picture shows the market value changes of our company and some genomic-related companies. It can be seen that the spur of gene sequencing technology has been in the late 1990s. The recession began in 2001-2003 and was a complete bubble. 2. Now we are in the midst of the second genome. This period from 2007 to 2008 is the second genomic boom. In fact, this boom is due to the emergence of a technology, the second-generation genome sequencing technology that everyone is now familiar with. This is a photo I took at Celera Genomics in 2000. The main job at the time was to do the sequencing of the first human genome. I can see that there were four hundred generations of sequencing equipment in the sequencing plant at the time. This is very spectacular. The phenomenon. But for now, 400 ABI3700 generations of sequencers are not as good as a second-generation sequencer. Therefore, the technological innovation and revolution are very fast. 3. The development of proteomic technology provides another growth point for clinical medical testing. Protein is a direct participant in life activities and therefore the ultimate embodiment of the state of life. Compared with genetic molecules, proteins are more directly responsible for the state of the living body. The source of information for precision medicine should not rely solely on genetic information, and access to information on proteomics is equally important. I believe that the development of proteomics technology provides another growth point for clinical medical detection technology.
China Antibacterial Blend Suppliers
Here you can find the related products in Antibacterial Blend, we are professional manufacturer of Antibacterial blend. We focused on international export product development, production and sales. We have improved quality control processes of Antibacterial Blend to ensure each export qualified product.
If you want to know more about the products in Antibacterial Blend, please click the Product details to view parameters, models, pictures, prices and Other information about Antibacterial Blend.
Whatever you are a group or individual, we will do our best to provide you with accurate and comprehensive message about Antibacterial Blend!
Salicylic Acid,BHA,O-hydroxybenzoic acid,Allantoin Xi'an Gawen Biotechnology Co., Ltd , https://www.ahualynbio.com